<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879176</url>
  </required_header>
  <id_info>
    <org_study_id>1095/2013</org_study_id>
    <nct_id>NCT01879176</nct_id>
  </id_info>
  <brief_title>Cytokine Removal in Cardiopulmonary Bypass Patients</brief_title>
  <acronym>CytoSorb</acronym>
  <official_title>Effect of Cytokine Removal in Cardiopulmonary Bypass Patients Using the Cytosorb ™ Filter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CytoSorbents, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiopulmonary bypass (CPB) surgery initiates a systemic inflammatory response induced by
      extrinsic (e.g. anesthesia, contact activation within the extracorporeal circuit,
      endotoxemia) and intrinsic (e.g. tissue damage, endothelial cell activation,
      ischemia-reperfusion injury of myocardium) factors. Monocytes are important players in
      systemic inflammation and the main producers of pro- and antiinflammatory cytokines.
      Monocytes activated by the extracorporeal circuit lead to a dysregulation of inflammatory
      homeostasis, increased levels of proinflammatory plasma mediators such as TNF-a, IL-1β, IL-6
      and IL-18 are joined by antiinflammatory cytokines such as IL-10. This strong inflammatory
      response induces post surgical monocyte immunosuppression which is indicated by an impaired
      production of ex vivo LPS induced TNF-a production. Also malfunction of the peripheral
      circulation with increased lactate levels, pronounced fluid accumulation, increased need of
      vasopressors and cerebral dysfunction are observed. All of these factors may delay weaning
      from the ventilator, recovery of organ functions and discharge from ICU. Thus measures to
      decrease the inflammatory process have the potential to improve the perioperative course.

      Use of cytokine adsorbing circuit during CBP has an effect on circulation cytokine levels for
      the first 36 hours after surgery and induces a decreased inflammatory response for up to 3
      days post surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients, who have an elective cardiac surgical intervention with an expected CBP duration
      &gt;120 minutes (e.g.: valve surgery, coronary artery bypass graft (CABG), combined procedures)
      will be enrolled to the study after given informed consent.

      Patients, who decline will be asked to collect their secondary outcome data to create a &quot;real
      - life&quot; group and increase the number of patients in the control group. In this &quot;real - life&quot;
      group no additional blood samples will be taken.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IL-6</measure>
    <time_frame>1. Preoperative 2. Before CBP 3. After CPB 4. 2 hours after CPB 5. 24 hours 6. 48 hours 7. 120 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Elective Cardiac Surgical Interventions</condition>
  <arm_group>
    <arm_group_label>CytoSorb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No filter will be installed on the CPB machine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb</intervention_name>
    <arm_group_label>CytoSorb</arm_group_label>
    <other_name>Polymer Based Adsorption Systems</other_name>
    <other_name>ISO 13485:2003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective cardiac surgical intervention with an expected CBP duration &gt;120 minutes

        Exclusion Criteria:

          -  Emergency procedures

          -  Heart transplantation

          -  Elective left ventricular assist device (LVAD) implantation

          -  Pulmonary thromendarterectomy

          -  Declined informed consent

          -  Serum creatinine &gt; 2mg/dl

          -  Body mass index &lt; 18

          -  Age &lt; 18 years

          -  Pregnant woman

          -  Receiving chemotherapy or diagnosed with any disease state (e.g., AIDS) that has
             produced leukopenia

          -  Receiving antileukocyte drugs

          -  Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)

          -  CRP &gt; 2mg/dl

          -  History of Stroke

          -  Bilirubin &gt;2mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hiesmayr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin H Bernardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harald Rinösl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Friedrich Hoffelner</last_name>
    <role>Study Chair</role>
    <affiliation>General Hospital of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Spittler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominik Wiedemann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philipp Opfermann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divison of Cardiothoracic Anaesthesia and Intensive Care, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <results_reference>
    <citation>Bernardi MH, Rinoesl H, Dragosits K, Ristl R, Hoffelner F, Opfermann P, Lamm C, Preißing F, Wiedemann D, Hiesmayr MJ, Spittler A. Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care. 2016 Apr 9;20:96. doi: 10.1186/s13054-016-1270-0.</citation>
    <PMID>27059056</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <results_first_submitted>April 30, 2016</results_first_submitted>
  <results_first_submitted_qc>November 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2017</results_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Martin Bernardi</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CytoSorb</title>
          <description>For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .
CytoSorb</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>No filter will be installed on the CPB machine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients, who were allocated to treatment or control after randomization</population>
      <group_list>
        <group group_id="B1">
          <title>CytoSorb</title>
          <description>For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>No filter will be installed on the CPB machine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="30" upper_limit="81"/>
                    <measurement group_id="B2" value="69" lower_limit="50" upper_limit="81"/>
                    <measurement group_id="B3" value="67" lower_limit="30" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>IL-6</title>
        <time_frame>1. Preoperative 2. Before CBP 3. After CPB 4. 2 hours after CPB 5. 24 hours 6. 48 hours 7. 120 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CytoSorb</title>
            <description>For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No filter will be installed on the CPB machine.</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6</title>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" lower_limit="10.8" upper_limit="98.7"/>
                    <measurement group_id="O2" value="63.6" lower_limit="41.2" upper_limit="154.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.8" lower_limit="49.0" upper_limit="160.8"/>
                    <measurement group_id="O2" value="118.7" lower_limit="68.4" upper_limit="255.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.6" lower_limit="53.7" upper_limit="253.5"/>
                    <measurement group_id="O2" value="120.9" lower_limit="68.0" upper_limit="198.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours after CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" lower_limit="61.4" upper_limit="160.5"/>
                    <measurement group_id="O2" value="67.7" lower_limit="43.7" upper_limit="134.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours after CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0" upper_limit="8.3"/>
                    <measurement group_id="O2" value="8.2" lower_limit="0.8" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CytoSorb</title>
          <description>For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .
CytoSorb</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>No filter will be installed on the CPB machine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Martin H. Bernardi</name_or_title>
      <organization>Medical University of Vienna</organization>
      <phone>004314040041090</phone>
      <email>martin.bernardi@meduniwien.ac.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

